PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Incorporated (PRLD) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (2.9) | D+ (1.6) | C+ (2.8) | C (2.2) | C+ (2.6) | C (2.4) |
| 2026-11-07 | B- (2.9) | D+ (1.6) | C+ (2.8) | C (2.4) | C+ (2.7) | C (2.5) |
| 2026-10-31 | B- (2.9) | D+ (1.6) | B- (3.0) | C (2.5) | C+ (2.7) | C+ (2.5) |
| 2026-10-24 | B- (2.9) | D+ (1.6) | B- (2.9) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-10-17 | B- (3.0) | D+ (1.6) | B- (2.9) | C+ (2.6) | C+ (2.6) | C+ (2.6) |